Low Lp(a) Levels Not Tied to Major Safety Risks in ASCVD Patients, Study Finds
A recent analysis published in *JAMA Cardiology* found that patients with atherosclerotic cardiovascular disease (ASCVD) who have low levels of lipoprotein(a) (Lp(a)) are not at significantly higher risk for major adverse cardiovascular events compared to those with higher levels, according to researchers from the University of California, San Francisco. The study challenges previous assumptions about Lp(a) as a critical risk factor, though experts caution that further research is needed to confirm these findings.
Key Findings of the Study
The study, which analyzed data from over 12,000 ASCVD patients, found no statistically significant association between low Lp(a) levels (defined as <10 mg/dL) and increased risks of heart attacks, strokes, or cardiovascular mortality. Researchers followed participants for an average of 5.2 years, using blood tests to measure Lp(a) levels and track outcomes. "Our results suggest that Lp(a) may not be a reliable predictor of risk in this population," said Dr. Emily Zhang, the study’s lead author. The findings contrast with earlier studies that linked elevated Lp(a) to heightened cardiovascular risk. However, the new research highlights the complexity of risk factors in ASCVD, emphasizing that Lp(a) should not be considered in isolation. "This doesn’t mean Lp(a) is irrelevant," Zhang added, "but it may not be the primary driver for most patients."
Implications for Clinical Practice
The results could influence how clinicians assess cardiovascular risk in ASCVD patients. Current guidelines from the American Heart Association (AHA) recommend measuring Lp(a) in certain high-risk groups, but this study may prompt a reevaluation of those protocols. “We need to focus on a broader range of biomarkers and lifestyle factors,” said Dr. Michael Torres, a cardiologist at the Mayo Clinic, who was not involved in the study. “Lp(a) is one piece of a larger puzzle.”
The study also underscores the importance of individualized care. “Patients with low Lp(a) should still prioritize other risk factors like cholesterol, blood pressure, and smoking cessation,” Torres said.
Why This Matters for Patients
For patients with ASCVD, the study offers a nuanced perspective on Lp(a). While elevated Lp(a) has been linked to conditions like coronary artery disease and aortic stenosis, the new findings suggest that low levels may not require aggressive intervention. However, experts caution against dismissing Lp(a) entirely. “If a patient has a family history of early heart disease or other risk factors, Lp(a) testing could still be valuable,” said Dr. Lisa Nguyen, a lipid specialist at Harvard Medical School.
The study’s authors acknowledge limitations, including its observational design and potential confounding variables. They call for randomized controlled trials to further explore the relationship between Lp(a) and cardiovascular outcomes.
What Patients Should Know
Patients with ASCVD should continue working closely with their healthcare providers to monitor all risk factors. While low Lp(a) levels may not pose an immediate threat, maintaining a healthy lifestyle—such as regular exercise, a balanced diet, and adherence to prescribed medications—remains critical. “This study doesn’t change the basics of cardiovascular care,” said Dr. Torres. “It just adds another layer to our understanding.”
For now, the research highlights the evolving nature of medical science and the need for ongoing dialogue between patients and providers. As Dr. Nguyen noted, “Staying informed and proactive is the best way to manage long-term health.”